If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Trulicity ® (dulaglutide) injection
0.75 mg/0.5 mL, 1.5 mg/0.5 mL, 3mg/0.5mL, 4.5mg/0.5mL
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
TRULICITY® (dulaglutide): Gastroparesis
Trulicity (dulaglutide) has not been studied in patients with severe or preexisting gastroparesis.
Dulaglutide slows gastric emptying.1
The use of dulaglutide may be associated with GI adverse reactions, sometimes severe.1
Dulaglutide has not been studied in patients with severe GI disease, including severe or preexisting gastroparesis, and is therefore not recommended in these patients.1
Enclosed Prescribing Information
1Trulicity [package insert]. Indianapolis, IN: Eli Lilly and Company; 2021.
GI = gastrointestinal
Date of Last Review: May 11, 2021